FibroGen (FGEN) Revenue & Revenue Breakdown


OverviewForecastOwnershipFinancialsChartTranscripts

FibroGen Revenue Highlights


Latest Revenue (Y)

$147.75M

Latest Revenue (Q)

$50.64M

Main Segment (Y)

Drug Product Revenue

Main Geography (Y)

CHINA

FibroGen Revenue by Period


FibroGen Revenue by Year

DateRevenueChange
2023-12-31$147.75M4.99%
2022-12-31$140.73M-40.19%
2021-12-31$235.31M33.46%
2020-12-31$176.32M-31.28%
2019-12-31$256.58M20.48%
2018-12-31$212.96M69.46%
2017-12-31$125.67M-30.02%
2016-12-31$179.58M-0.69%
2015-12-31$180.83M31.41%
2014-12-31$137.60M34.68%
2013-12-31$102.17M54.96%
2012-12-31$65.93M-

FibroGen generated $147.75M in revenue during NA 2023, up 4.99% compared to the previous quarter, and up 69.38% compared to the same period a year ago.

FibroGen Revenue by Quarter

DateRevenueChange
2024-06-30$50.64M-9.41%
2024-03-31$55.90M105.99%
2023-12-31$27.14M-32.38%
2023-09-30$40.13M-9.44%
2023-06-30$44.32M22.56%
2023-03-31$36.16M5.22%
2022-12-31$34.37M118.41%
2022-09-30$15.73M-47.21%
2022-06-30$29.81M-51.00%
2022-03-31$60.83M267.69%
2021-12-31$16.54M-89.39%
2021-09-30$155.97M540.18%
2021-06-30$24.36M-36.60%
2021-03-31$38.43M-40.88%
2020-12-31$65.00M47.62%
2020-09-30$44.03M2.67%
2020-06-30$42.89M75.76%
2020-03-31$24.40M206.01%
2019-12-31$7.97M-75.96%
2019-09-30$33.17M-82.68%
2019-06-30$191.57M702.77%
2019-03-31$23.86M-77.92%
2018-12-31$108.05M272.25%
2018-09-30$29.03M-33.96%
2018-06-30$43.95M37.67%
2018-03-31$31.93M-24.90%
2017-12-31$42.51M55.87%
2017-09-30$27.27M-5.95%
2017-06-30$29.00M7.83%
2017-03-31$26.89M-15.73%
2016-12-31$31.91M6.01%
2016-09-30$30.10M-66.28%
2016-06-30$89.28M215.68%
2016-03-31$28.28M15.71%
2015-12-31$24.44M25.10%
2015-09-30$19.54M-83.79%
2015-06-30$120.55M639.66%
2015-03-31$16.30M1.20%
2014-12-31$16.11M17.88%
2014-09-30$13.66M-84.81%
2014-06-30$89.96M403.23%
2014-03-31$17.88M44.28%
2013-12-31$12.39M-82.61%
2013-09-30$71.25M-

FibroGen generated $50.64M in revenue during Q2 2024, up -9.41% compared to the previous quarter, and up 140.04% compared to the same period a year ago.

FibroGen Revenue Breakdown


FibroGen Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21Dec 20Dec 19
Drug Product Revenue$18.75M$11.09M$962.00K$8.91M-
Product---$89.03M$-34.62M
A P I Product----$-36.32M
Drug Product----$2.80M

FibroGen's latest annual revenue breakdown by segment (product or service), as of Dec 23: Drug Product Revenue (100.00%).

Quarterly Revenue by Product

Product/ServiceSep 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Mar 21Dec 20Sep 20Jun 20Mar 20Sep 19
Product$46.21M$30.54M$29.39M$35.92M$27.90M$19.83M$5.37M$579.00K---------
Drug Product Revenue$-262.00K$24.49M$1.05M$1.32M$14.27M$2.11M$6.48M$1.09M$7.59M$1.13M$8.48M$686.00K$8.24M----
License--$2.65M--------------
Royalty-------$200.00K---------

FibroGen's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Product (100.57%), and Drug Product Revenue (-0.57%).

FibroGen Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 23Dec 22Dec 21Dec 20Dec 19
Europe$9.55M$33.82M$131.24M$67.16M$132.40M
CHINA$109.38M$84.63M$55.64M$72.50M-
UNITED STATES$12.96M$12.52M$46.12M--
JAPAN$15.87M$9.76M$2.31M$36.66M-
All Other----$1.70M

FibroGen's latest annual revenue breakdown by geography, as of Dec 23: CHINA (74.03%), JAPAN (10.74%), UNITED STATES (8.77%), and Europe (6.46%).

Quarterly Revenue by Country

CountrySep 24Mar 24Dec 23Jun 23Mar 23
CHINA$4.50M$2.10M$104.38M$4.70M$300.00K

FibroGen's latest quarterly revenue breakdown by geography, as of Sep 24: CHINA (100.00%).

FibroGen Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
BMRNBioMarin Pharmaceutical$2.42B$733.87B
BPMCBlueprint Medicines$249.38M$128.18M
STROSutro Biopharma$153.73M$25.71M
FGENFibroGen$147.75M$50.64M
ARDXArdelyx$124.46M$98.24M
MRUSMerus$43.95M$11.77M
AGIOAgios Pharmaceuticals$26.82M$8.96M
RVMDRevolution Medicines$11.58M-
MREOMereo BioPharma Group$10.00M-
STOKStoke Therapeutics$8.78M$4.89M
LYELLyell Immunopharma$130.00K$34.00K
CGEMCullinan Oncology--
VSTMVerastem-$10.00M
PCVXVaxcyte--
GOSSGossamer Bio-$9.48M
DAWNDay One Biopharmaceuticals-$20.07M
ZURAZura Bio--
BMEABiomea Fusion--
SNDXSyndax Pharmaceuticals-$12.50M
LRMRLarimar Therapeutics--
GLUEMonte Rosa Therapeutics-$4.70M
AKROAkero Therapeutics--
HEPAHepion Pharmaceuticals--

FGEN Revenue FAQ


What is FibroGen’s yearly revenue?

FibroGen's yearly revenue for 2023 was $147.75M, representing an increase of 4.99% compared to 2022. The company's yearly revenue for 2022 was $140.73M, representing a decrease of -40.19% compared to 2021. FGEN's yearly revenue for 2021 was $235.31M, representing an increase of 33.46% compared to 2020.

What is FibroGen’s quarterly revenue?

FibroGen's quarterly revenue for Q2 2024 was $50.64M, a -9.41% decrease from the previous quarter (Q1 2024), and a 14.26% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $55.9M, a 105.99% increase from the previous quarter (Q4 2023), and a 54.59% increase year-over-year (Q1 2023). FGEN's quarterly revenue for Q4 2023 was $27.14M, a -32.38% decrease from the previous quarter (Q3 2023), and a -21.03% decrease year-over-year (Q4 2022).

What is FibroGen’s revenue growth rate?

FibroGen's revenue growth rate for the last 3 years (2021-2023) was -37.21%, and for the last 5 years (2019-2023) was -42.41%.

What are FibroGen’s revenue streams?

FibroGen's revenue streams in c 23 are Drug Product Revenue

What is FibroGen’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of FibroGen was Drug Product Revenue. This segment made a revenue of $18.75M, representing 100.00% of the company's total revenue.